The FDA’s final bioresearch monitoring (BIMO) guidance brings greater clarity to BIMO inspections across the clinical research landscape. Rather than introducing new rules, it consolidates expectations for FDA inspections in clinical trials, helping sponsors, CROs, investigators, and institutional review boards (IRBs) better understand how inspections are conducted.
This article reviews:
- What is new in this guidance compared to previous versions, such as details on the inspection life cycle, electronic systems readiness, and expectations for timely, structured responses
- Why the FDA’s clarity is important, even if readers are already familiar with BIMO
- What investigators, sites, sponsor, CROs, and IRBs gain from the guidance, and what they need to do next
For organizations focused on inspection readiness and clinical research compliance, this clarity helps reduce uncertainty and improve preparation.
Read the full article on Clinical Leader.
